MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-β/Smad2/STAT3/STAT5 pathway

Molecular Medicine Reports

Volumn 11, Issue 5, 2015, Pages 3854-3859

  Sun, Wei ^a   Ma, Yiping ^b   Chen, Peng ^c   Wang, Dong ^c  

^a TIANJIN CHEST HOSPITAL   (China)

^b TIANJIN HUANHU HOSPITAL   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy resistance; Human lung cancer; MicroRNA 10a

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASPASE 3; CASPASE 8; CISPLATIN; INITIATION FACTOR 4E; MICRORNA; MICRORNA 10A; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; RHODAMINE 123; SMAD2 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN10 MICRORNA, HUMAN;

A549 CELL LINE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RESISTANCE; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; DRUG RESISTANCE; GENETICS; LUNG TUMOR; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APSEUDES; EUKARYOTA;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; HUMANS; LUNG NEOPLASMS; MICRORNAS; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

EID: 84922318943     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3181     Document Type: Article

References (21)

1. Joshi P, Middleton J, Jeon YJ and Garofalo M: MicroRNAs in lung cancer. World J Methodol2: 5972, 2014.
2. Liu R, Liu X, Zheng Y, Gu J, Xiong S, Jiang P, Jiang X, Huang E, Yang Y, Ge D and Chu Y: MicroRNA7 sensitizes nonsmall cell lung cancer cells to paclitaxel. Oncol Lett 5: 21932200, 2014.
3. Cai J, Fang L, Huang Y, Li R, Yuan J, Yang Y, Zhu X, Chen B, Wu J and Li M: miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res 73: 5402-5415, 2013.
4. Ayaz L, Görür A, Yaroʇlu HY, Ozcan C and Tamer L: Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma. J Cancer Res Clin Oncol 139: 1499-1506, 2013.
5. Köhler CU, Bryk O, Meier S, Lang K, Rozynek P, Brüning T and Käfferlein HU: Analyses in human urothelial cells identify methylation of miR-152, miR-200b and miR-10a genes as candidate bladder cancer biomarkers. Biochem Biophys Res Commun 438: 48-53, 2013.
6. Zhu Y, Liu XJ, Yang P, Zhao M, Lv LX, Zhang GD, Wang Q and Zhang L: Alkylglyceronephosphate synthase (AGPS) alters lipid signaling pathways and supports chemotherapy resistance of glioma and hepatic carcinoma cell lines. Asian Pac J Cancer Prev 7: 32193226, 2014.
7. Ulasli SS, Celik S, Gunay E, Ozdemir M, Hazman O, Ozyurek A, Koyuncu T and Unlu M: Anticancer Effects of Thymoquinone, Caffeic Acid Phenethyl Ester and Resveratrol on A549 Non-small Cell Lung Cancer Cells Exposed to Benzo(a)pyrene. Asian Pac J Cancer Prev 14: 6159-6164, 2013.
8. Sun PL, Jin Y, Kim H, Seo AN, Jheon S, Lee CT and Chung JH: Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma. Virchows Arch 463: 427-436, 2013.
9. Zhang C, Zhou F, Li N, Shi S, Feng X, Chen Z, Hang J, Qiu B, Li B, Chang S, et al: Overexpression of RhoE has a prognostic value in non-small cell lung cancer. Ann Surg Oncol 14: 2628-2635, 2007.
10. Prochazka L, Koudelka S, Dong LF, Stursa J, Goodwin J, Neca J, Slavik J, Ciganek M, Masek J, Kluckova K, et al: Mitochondrial targeting overcomes ABCA1-dependent resistance of lung carcinoma to α -tocopheryl succinate. Apoptosis 18: 286-299, 2013.
11. Minami T, Kijima T, Otani Y, Kohmo S, Takahashi R, Nagatomo I, Hirata H, Suzuki M, Inoue K, Takeda Y, et al: HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer. Mol Cancer Ther 11: 830-841, 2012.
12. Wang YS, Miao LY, Liu L, Cai HR, Ding JJ, Ren SX, Zhou CC and Schmid-Bindert G: Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinical outcome of erlotinib treatment. Chin Med J (Engl) 126: 3931-3935, 2013.
13. Cha Y, Kim DK, Hyun J, Kim SJ and Park KS: A3 binds to TGF-beta receptor I and induces Smad-independent, JNK-dependent apoptosis in ovarian cancer cells. Cell Signal 25: 1245-1251, 2013.
14. Zhang K, Zhang Y, Liu C, Xiong Y and Zhang J: MicroRNAs in the diagnosis and prognosis of breast cancer and their therapeutic potential. Int J Oncol 3: 950958, 2014.
15. Li Y, Li L, Guan Y, Liu X, Meng Q and Guo Q: MiR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN. Biochem Biophys Res Commun 440: 604-610, 2013.
16. Avasarala S, Bikkavilli RK, Van Scoyk M, Zhang W, Lapite A, Hostetter L, Byers JT, Heasley LE, Sohn JW and Winn RA: Heterotrimeric g-protein, gα16, is a critical downstream effector of non-canonical wnt signaling and a potent inhibitor of transformed cell growth in non small cell lung cancer. PLoS One 8: e76895, 2013.
17. Surowiak P, Pawełczyk K, Maciejczyk A, Pudełko M, Kołodziej J, Zabel M, Murawa D, Drag M, Gansukh T, Dietel M and Lage H: Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer. Anticancer Res 28 (5B): 2967-2974, 2008.
18. Ak Y, Demirel G and Gülbas Z: MDR1, MRP1 and LRP expression in patients with untreated acute leukaemia: correlation with 99mTc-MIBI bone marrow scintigraphy. Nucl Med Commun 28: 541-546, 2007.
19. Wang L, Deng Q, Wang J, Bai X, Xiao X, Lv HR, Zhao MF and Liu PJ: Effect of CIK on multidrugresistance reversal and increasing the sensitivity of ADR in K562/ADR cells. Oncol Lett 4: 17781782, 2014.
20. Kin R, Kato S, Kaneto N, Sakurai H, Hayakawa Y, Li F, Tanaka K, Saiki I and Yokoyama S: Procyanidin C1 from Cinnamomi Cortex inhibits TGF-β -induced epithelial-to-mesenchymal transition in the A549 lung cancer cell line. Int J Oncol 43:1901-1906, 2013.
21. Tu B, Peng ZX, Fan QM, Du L, Yan W and Tang TT: Osteosarcoma cells promote the production of pro-tumor cytokines in mesenchymal stem cells by inhibiting their osteogenic differentiation through the TGF-β/Smad2/3 pathway. Exp Cell Res 320:164-173, 2014.